Literature DB >> 16233969

Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.

N S Sieber-Ruckstuhl1, F S Boretti, M Wenger, C Maser-Gluth, C E Reusch.   

Abstract

Trilostane is thought to be a competitive inhibitor of the 3beta-hydroxysteroid dehydrogenase (3beta-HSD), an essential enzyme system for the synthesis of cortisol, aldosterone and androstenedione. Due to its reliable clinical efficacy, trilostane is increasingly used to treat dogs with pituitary-dependant hyperadrenocorticism (PDH). The objective of our study was to investigate the effect of trilostane on precursor concentrations located before (17alpha-OH-pregnenolone, dehydroepiandrostenedione) and after (17alpha-OH-progesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol) the proposed enzyme inhibition, on end products of steroid biosynthesis (cortisol and aldosterone) and on endogenous adrenocorticotrophic hormone (ACTH) concentrations in dogs with PDH. Hormones of the steroid biosynthesis pathway were evaluated in 15 dogs before and 1h after injection of synthetic ACTH prior to (t(0)), in weeks 1-2 (t(1)) and in weeks 3-7 (t(2)) of trilostane treatment. Endogenous ACTH concentrations were measured at the same time points before performing the ACTH stimulation test. During trilostane treatment baseline and post-stimulation cortisol concentrations decreased significantly. Baseline serum aldosterone levels showed a significant increase; post-stimulation values decreased. Baseline and post-stimulation 17alpha-OH-pregnenolone and dehydroepiandrostenedione concentrations increased significantly. 17alpha-OH-progesterone and androstenedione levels did not change. Post-stimulation 21-deoxycortisol concentrations decreased significantly, baseline 11-deoxycortisol concentrations increased significantly. Endogenous ACTH levels showed a significant increase. The significant increase in 17alpha-OH-pregnenolone and dehydroepiandrostenedione concentrations confirms an inhibitory effect of trilostane on the 3beta-HSD. Since 17alpha-OH-progesterone concentrations did not change, but cortisol concentrations markedly decreased, trilostane seems to influence additional enzymes of the hormone cascade, like the 11beta-hydroxylase and possibly the 11beta-hydroxysteroid dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16233969     DOI: 10.1016/j.domaniend.2005.09.004

Source DB:  PubMed          Journal:  Domest Anim Endocrinol        ISSN: 0739-7240            Impact factor:   2.290


  9 in total

1.  The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study.

Authors:  C Ouschan; M Lepschy; F Zeugswetter; E Möstl
Journal:  Vet Res Commun       Date:  2011-11-25       Impact factor: 2.459

Review 2.  Update on the use of trilostane in dogs.

Authors:  Julie Lemetayer; Shauna Blois
Journal:  Can Vet J       Date:  2018-04       Impact factor: 1.008

3.  Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.

Authors:  C M Bonadio; E C Feldman; T A Cohen; P H Kass
Journal:  J Vet Intern Med       Date:  2014-05-26       Impact factor: 3.333

4.  Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  L E Reid; E N Behrend; L G Martin; R J Kemppainen; C R Ward; J C Lurye; T C Donovan; H P Lee
Journal:  J Vet Intern Med       Date:  2014-01-08       Impact factor: 3.333

5.  Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.

Authors:  Stefania Golinelli; Viviani de Marco; Rodolfo Oliveira Leal; Andrea Barbarossa; Camilla Aniballi; Elisa Maietti; Antonio Maria Tardo; Sara Galac; Federico Fracassi
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

6.  Evaluation of aldosterone concentrations in dogs with hypoadrenocorticism.

Authors:  M E Baumstark; N S Sieber-Ruckstuhl; C Müller; M Wenger; F S Boretti; C E Reusch
Journal:  J Vet Intern Med       Date:  2013-11-15       Impact factor: 3.333

7.  Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  C Griebsch; C Lehnert; G J Williams; K Failing; R Neiger
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

8.  Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  Carolina Arenas Bermejo; Dolores Pérez Alenza; Paula García San José; Lidia Llauet; Laura Pérez-López; Carlos Melián; Edward C Feldman
Journal:  J Vet Intern Med       Date:  2020-06-13       Impact factor: 3.333

9.  Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment.

Authors:  Paula García San José; Carolina Arenas Bermejo; Daniel Alonso-Miguel; Irene Clares Moral; Pedro Cuesta-Alvaro; María Dolores Pérez Alenza
Journal:  J Vet Intern Med       Date:  2020-12-04       Impact factor: 3.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.